VistaGen Therapeutics, Sanwa Kagaku Kenkyusho Co., RainDance Technologies, Becton Dickinson, National Institutes of Health, Galapagos — BioFocus DPI, University College London | GenomeWeb
Sanwa Licenses VistaGen's ES Cell Assays for Diabetes Drug Development
 
Japanese pharmaceutical firm Sanwa Kagaku Kenkyusho has licensed VistaGen Therapeutics’ embryonic stem cell-based assay systems for use in diabetes drug development, VistaGen said this week.
 
Under the terms of the license agreement, Sanwa will use three of VistaGen’s customized beta-islet differentiation assay systems to identify and screen new small-molecule drug candidates to treat type 1 and type 2 diabetes.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.